TWO · 6917.TWO
Andros Pharmaceuticals Co.,Ltd
NT$32.25-NT$0.90 (-2.71%)
Andros Pharmaceuticals Co.,Ltd’s quoted price sits in the lower half of its reported 52-week range, 29.82% below the high.
Loading market information…
TWO · 4192.TWO · TWD
Stock price
Quote as of Oct 30, 2026, 05:33 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
SynCore Biotechnology Co.,Ltd’s quoted price sits in the lower half of its reported 52-week range, 41.32% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
SynCore Biotechnology Co.,Ltd, a Taiwan-based enterprise, specializes in the development and commercialization of biotechnology services, alongside offering expertise in food advisory and medicine inspection. The company's robust pipeline includes several promising drug candidates. Among its novel chemical entities (NCEs), SB01 is an injectable anti-cancer compound currently undergoing Phase II clinical trials for head and neck cancer. Another anti-cancer NCE, SB02, is in preclinical development, targeting stomach cancer. Beyond novel compounds, SynCore also markets established pharmaceutical solutions. This includes SB03-Veregen, an ointment prescribed for external genital and perianal warts. Its portfolio further extends to SB04, a conventional medication for age-related macular degeneration, presently in Phase II clinical studies. Additionally, SynCore is advancing SB05-EndoTAG, an established drug undergoing Phase III clinical trials for the treatment of both pancreatic cancer and triple-negative breast cancer. In a related venture, the company distributes epiCam brand cameras, which are designed for recording the progression of ophthalmic diseases. SynCore maintains strategic collaborations with notable entities such as Medigene AG, MacuCLEAR Inc., Sinphar Pharmaceutical Co., Ltd., and The National Health Research Institutes. Founded in 2008, SynCore Biotechnology Co.,Ltd is headquartered in Yilan City, Taiwan, and operates as a subsidiary of Sinphar Pharmaceutical Co., Ltd.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 12:27 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$32.25-NT$0.90 (-2.71%)
Andros Pharmaceuticals Co.,Ltd’s quoted price sits in the lower half of its reported 52-week range, 29.82% below the high.
NT$22.55-NT$0.35 (-1.53%)
Bio Preventive Medicine Corp.’s quoted price sits in the lower half of its reported 52-week range, 50.98% below the high.
NT$30.60-NT$0.05 (-0.16%)
Level Biotechnology Inc.’s quoted price sits in the lower half of its reported 52-week range, 11.82% below the high.
NT$15.40-NT$0.65 (-4.05%)
AmCad BioMed Corporation’s quoted price sits in the upper half of its reported 52-week range, 18.3% below the high.
NT$13.95-NT$0.05 (-0.36%)
LAUNXP Biomedical Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 45.19% below the high.
NT$36.00NT$0.00 (0.0%)
TCI GENE Inc.’s quoted price sits in the lower half of its reported 52-week range, 12.3% below the high.
NT$18.70+NT$0.20 (+1.08%)
Lukas Biomedical Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.46% below the high.
NT$15.50NT$0.00 (0.0%)
NatureWise Biotech & Medicals Corporation’s quoted price sits in the lower half of its reported 52-week range, 36.99% below the high.
